Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | SARS1 | P49591 | 1/20 | 0.42 |
| ▸ | IARS1 | P41252 | 1/20 | 0.42 |
| ▸ | MARS1 | P56192 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | HINT1 | P49773 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403858 | 1.00 | ADORA3 (0.51) | ADORA3NT5ELARS1DNMT1SARS1 | |
| SCHEMBL11910708 | 0.90 | ADORA3 (0.53) | ADORA3NT5ELARS1DNMT1SARS1 | |
| SCHEMBL278299 | 0.89 | RNASEL (0.49) | ADORA3NT5EDNMT1ADORA2AADORA2B | |
| SCHEMBL13403857 | 0.89 | RNASEL (0.49) | ADORA3NT5EDNMT1ADORA2AADORA2B | |
| SCHEMBL23629805 | 0.89 | LMNA (0.46) | ADORA3NT5ELARS1ADORA2AADORA1 | |
| SCHEMBL4757814 | 0.89 | ADORA3 (0.56) | ADORA3NT5EADORA2AADORA2BADORA1 | |
| SCHEMBL12799312 | 0.85 | ADORA3 (0.67) | ADORA3NT5ELARS1DNMT1SARS1 | |
| SCHEMBL18493293 | 0.85 | ADORA3 (0.67) | ADORA3NT5ELARS1DNMT1SARS1 | |
| SCHEMBL22220143 | 0.85 | ADORA1 (0.50) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL21859151 | 0.85 | ADORA1 (0.50) | ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183226-B2 | Myocardial perfusion imaging method | GILEAD SCIENCES, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8133879-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100272645-A1 | MYOCARDIAL PERFUSION IMAGING METHOD | GILEAD PALO ALTO, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100183503-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD PALO ALTO, INC. | 2010-07-22 | — | — | US | disclosed |
| US-7683037-B2 | A2A receptor agonist; regadenoson (CVT-3146); produces coronary vasodilation without significant peripheral vasodilation; | GILEAD PALO ALTO, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7553823-B2 | C-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090081120-A1 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20070207978-A1 | C-Pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183503-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885NT5E 123/4885LARS1 2806/4885 |
| US-20100272645-A1 | MYOCARDIAL PERFUSION IMAGING METHOD | ADORA2A, ADORA3, ADORA2B | ADORA3 2/4885NT5E 31/4885LARS1 4086/4885 |
| US-20070207978-A1 | C-Pyrazole A2A receptor agonists | ADORA2A, ADORA3, TBXA2R | ADORA3 2/4885NT5E 381/4885LARS1 4107/4885 |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885NT5E 139/4885LARS1 3303/4885 |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | ADORA2A, ADORA3, ADRB3 | ADORA3 2/4885NT5E 56/4885LARS1 4010/4885 |
| US-20090081120-A1 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods | ADORA2A, FABP3, ADORA3 | ADORA3 3/4885NT5E 111/4885LARS1 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.